Know Cancer

forgot password

Effect of Body Mass on Filgrastim Pharmacokinetics

18 Years
Open (Enrolling)
Hematological Malignancy, Pharmacokinetics of Filgrastim

Thank you

Trial Information

Effect of Body Mass on Filgrastim Pharmacokinetics

Inclusion Criteria:

- Age greater than or equal to 18 years

- Receiving filgrastim at 5mcg/kg ± 10%

- Admitted as an inpatient with an expected stay of at least 24 hours

- Weight is > 190% of their ideal body weight (IBW) for "obese" patients or within 80 -
124% of IBW for matched control patients.

- Patient or their legally authorized representative understands and voluntarily signs
the written informed consent prior to any study-specific procedures. A copy of the
signed informed consent form will be retained by the treating institution.

Exclusion Criteria:

- Patients who have received filgrastim within 24 hours prior to enrollment

- Patients who have received pegfilgrastim within 14 days prior to enrollment

- Hypersensitivity reaction to filgrastim or any related product

- Patients who have taken lithium within 7 days of enrollment

- Serum Creatinine > 1.5 mg/dL

- Patients who are pregnant or breastfeeding

- Patients who are unable to understand and/or render informed consent

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Systemic clearance of filgrastim in obese and non-obese patients

Outcome Time Frame:

24 hours

Safety Issue:


Principal Investigator

Aaron Cumpston, PharmD

Investigator Role:

Principal Investigator

Investigator Affiliation:

West Virginia University


United States: Institutional Review Board

Study ID:

WVU 021112



Start Date:

October 2012

Completion Date:

February 2014

Related Keywords:

  • Hematological Malignancy
  • Pharmacokinetics of Filgrastim
  • Filgrastim
  • Obese
  • Non-obese
  • Pharmacokinetics
  • Neoplasms
  • Hematologic Neoplasms



West Virginia University Mary Babb Randolph Cancer CenterMorgantown, West Virginia  26506